Biocure Technology Inc. announces that it has entered into an exclusive letter agreement dated September 8, 2023 with Atriva Therapeutics GmbH. whereby the Company will acquire all of the issued.
Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the resulting entity will continue the business of Atriva Therapeutics. Shareholders of Atriva will receive not less than 75% of the securities of the resulting issuer, with the current shareholders of Biocure Technology holding the remainder. The transaction is subject to various terms and conditions, including
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to what action you should take, you are recommended to seek your own financial advice. | June 6, 2023
Respiratory Syncytial Virus Clinical Trial Pipeline Insights | 50+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.
EQS-News: Adrenomed AG / Key word(s): PersonnelAdrenomed appoints Dr. Stephan Witte as Chief Medical Officer 01.02.2023 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release Adrenomed appoints Dr. Stephan Witte as Chief Medical Officer Hennigsdorf/Berlin (Germany),.